Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Rhythm Pharmaceuticals, Inc.

NASDAQ: RYTM · Life Sciences · 2 alerts · CIK 1649904

Share price
$107.48Close, Nov 16
Market cap
$7.45B
Shares outstanding
69.33MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Rhythm Pharmaceuticals, Inc. filings on SEC EDGAR ↗

4:09 PM ET 10-Q
Financial Results

Rhythm Pharmaceuticals Q3 2026 Results: Net Loss of $41.4M, Loss Narrows

Rhythm Pharmaceuticals reported total revenues of $223.5 million for the nine months ended September 30, 2026, a significant increase from $132.5 million in the prior year period. Despite the revenue growth, the company recorded a net loss of $146.3 million due to increased selling, general, and administrative expenses and research and development costs.

Key figure
Net loss $41.4M
8:11 AM ET 8-K
Financial Results

Rhythm Pharmaceuticals Financial Results

Rhythm Pharmaceuticals reported Q3 2026 net product revenue of $92.1 million, a 29% sequential increase driven by the strong U.S. launch of IMCIVREE for acquired hypothalamic obesity. The company also secured a five-year term loan facility for up to $750 million and announced plans to advance bivamelagon into pivotal development for Prader-Willi syndrome.

Term
Q3 2026

“Rhythm continues to make strong progress in bringing IMCIVREE® (setmelanotide) to patients with acquired hypothalamic obesity (HO), highlighted by continued commercial momentum in the United States. Our commercial launch in Japan represents another important milestone in a market with the potential to become our second largest.”

David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm Pharmaceuticals

“We are excited about advancing our next-generation MC4R agonists, beginning with bivamelagon. Strong clinical results have reinforced our confidence in its potential across multiple indications, and we look forward to initiating pivotal trials in acquired HO and Prader-Willi syndrome.”

David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm Pharmaceuticals

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.